The inclusion compound of a new ionizable derivative of beta-cyclodextrin with ferrocenium drug.
A new beta-cyclodextrin (beta-CD) derivative, mono[6-deoxy-6-(2-butenedinitrile-2,3-dimercapto sodium salt)]-beta-CD (6-mnt-beta-CD), and its inclusion compound with a ferrocenium drug, have been prepared and characterized by IR, UV, 13C-NMR spectroscopy, and mass spectrometry, elemental analysis, thermogravimetry, and cyclic voltammetry (CV). The interplay between the side-arm anion of beta-CD and the ferrocenium (guest) in the inclusion compound 6-mnt-beta-CD-/Fc+ has been investigated by 13C-NMR, UV, IR, and thermogravimetric methods. Charge transfer from the anion to the cation in 6-mnt-beta-CD-/Fc+ was then experimentally identified. The interaction between the guest and the host with side-arm in 6-mnt-beta-CD-/Fc+ resulted in smaller positive potential shifts compared to that in the inclusion compound [beta-CD/Fc+]BF4-.
Lu
C S
CS
Coordination Chemistry Institute, State Key Laboratory of Coordination Chemistry, Nanjing University, PR China.
Ren
X M
XM
Hu
C J
CJ
Zhu
H Z
HZ
Meng
Q J
QJ
D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003505:Cyclodextrins / Q000138:chemical synthesis* / Q000737:chemistry; D004355:Drug Stability; D005296:Ferrous Compounds / Q000138:chemical synthesis* / Q000737:chemistry; D006358:Hot Temperature; D009682:Magnetic Resonance Spectroscopy; D013056:Spectrophotometry, Ultraviolet; D013696:Temperature; D047392:beta-Cyclodextrins
D000970:Antineoplastic Agents; D003505:Cyclodextrins; D005296:Ferrous Compounds; D047392:beta-Cyclodextrins; C064804:ferrocenium; C031215:betadex